Stanford tests arthritis drug to tame dangerous heart inflammation
NCT ID NCT06868381
Summary
This study is testing if adding the drug baricitinib to standard therapy can better control active inflammation in the hearts of adults with cardiac sarcoidosis. Ten participants will take the drug combination for 16 weeks while doctors monitor their heart scans and symptoms. The main goal is to see if the treatment reduces the heart inflammation visible on special PET scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304-2210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.